BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8693970)

  • 1. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
    Bogdanov AB; Luk'ianov IV; Veliev EI
    Urologiia; 2006; (5):59-63. PubMed ID: 17444154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF
    Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
    Ugeskr Laeger; 1996 Sep; 158(36):5030-5. PubMed ID: 8928243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia].
    Pytel' IuA; Vinarov AZ
    Urol Nefrol (Mosk); 1996; (4):25-7. PubMed ID: 8928344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
    Helfand BT; Blackwell RH; McVary KT
    J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L; Manieri C; Paradiso Galatioto G; Vicentini C
    Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H; Chen J; Braf Z
    Harefuah; 1993 Dec; 125(12):453-6, 496. PubMed ID: 7509305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA
    Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs.
    Iguer-Ouada M; Verstegen JP
    J Reprod Fertil Suppl; 1997; 51():139-49. PubMed ID: 9404280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.